N-(2-(1H-indol-3-yl)ethyl)-4-butoxybenzenesulfonamide | 880139-14-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-(1H-indol-3-yl)ethyl)-4-butoxybenzenesulfonamide
• 英文别名: 4-butoxy-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide
• CAS: 880139-14-0
• 化学式: C₂₀H₂₄N₂O₃S
• 分子量: 372.488
• InChiKey: SFIDYRMKQHYGNT-UHFFFAOYSA-N

物化性质

• 沸点：
  582.6±60.0 °C(Predicted)
• 密度：
  1.228±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  79.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(2-(1H-indol-3-yl)ethyl)-4-butoxybenzenesulfonamide 、 N-(4-氯苯基)-2-氯乙酰胺 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以17.3%的产率得到N-(4-chlorophenyl)-2-(3-(2-(4-butoxyphenylsulfonamido)ethyl)-1H-indol-1-yl)acetamide
  参考文献：
  名称：

  Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors

  摘要：

  Atrial fibrillation (AF) is one of the common arrhythmias that threaten human health. Kv1.5 potassium channel is reported as an efficacious and safe target for the treatment of AF. In this paper, we designed and synthesized three series of compounds through modifying the lead compound RH01617 that was screened out by the pharmacophore model we reported earlier. All of the compounds were evaluated by the whole-patch lamp technology and most of them possessed potent inhibitory activities against Kv1.5. Compounds IIIi and IIIl were evaluated for the target selectivity as well as the pharmacodynamic effects in an isolated rat model. Due to the promising pharmacological behavior, compound IIIl deserves further pharmacodynamic and pharmacokinetic evaluations. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.08.041
• 作为产物：
  描述：

  sodium p-hydroxybenzenesulfonate 在 氯化亚砜 、 三乙胺 、 N,N-二甲基甲酰胺 、 sodium hydroxide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成 N-(2-(1H-indol-3-yl)ethyl)-4-butoxybenzenesulfonamide
  参考文献：
  名称：

  Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors

  摘要：

  Atrial fibrillation (AF) is one of the common arrhythmias that threaten human health. Kv1.5 potassium channel is reported as an efficacious and safe target for the treatment of AF. In this paper, we designed and synthesized three series of compounds through modifying the lead compound RH01617 that was screened out by the pharmacophore model we reported earlier. All of the compounds were evaluated by the whole-patch lamp technology and most of them possessed potent inhibitory activities against Kv1.5. Compounds IIIi and IIIl were evaluated for the target selectivity as well as the pharmacodynamic effects in an isolated rat model. Due to the promising pharmacological behavior, compound IIIl deserves further pharmacodynamic and pharmacokinetic evaluations. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.08.041

文献信息

• [EN] NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF<br/>[FR] NOUVEAU COMPOSÉ, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  申请人：DAEGU GYEONGBUK MEDICAL INNOVATION FOUND

  公开号：WO2021145729A1

  公开（公告）日：2021-07-22

  The present invention relates to a method for preparing a biomaterial having selectively functionalized tyrosine, a biomaterial having selectively functionalized tyrosine, and a pharmaceutical composition containing the same as an active ingredient. The method for preparing a biomaterial to which a compound represented by formula 2 is coupled, of the present invention, allows the compound represented by formula 2 to be selectively coupled, in a high yield in a biomaterial, to tyrosine, which is present on the surface of an aqueous solution such that the coupling thereof to amino acids other than tyrosine does not occur and, when only one tyrosine is present, heterogeneous mixtures are not present and the inherent activity of the biomaterial is maintained, and thus the compound can be effectively used as a pharmaceutical composition containing a biomaterial drug as an active ingredient. In addition, the method can selectively functionalize tyrosine, and thus can be effectively used for tyrosine functionalization in a biomaterial.

  本发明涉及一种制备具有选择性功能化酪氨酸的生物材料的方法，具有选择性功能化酪氨酸的生物材料，以及含有该生物材料作为活性成分的药物组合物。本发明的一种制备生物材料的方法，其中将由式2表示的化合物偶联到生物材料，使得该化合物能够选择性地偶联到酪氨酸，且在生物材料中的产率较高，酪氨酸位于水溶液表面，使得其与酪氨酸以外的氨基酸不发生偶联，当只有一个酪氨酸存在时，不会出现异质混合物，同时保持生物材料的固有活性，因此该化合物可以有效地用作含有生物材料药物的药物组合物的活性成分。此外，该方法可以选择性功能化酪氨酸，因此可以有效地用于生物材料中的酪氨酸功能化。
• Inhibitors of 15-lipoxygenase
  申请人：Murugesan Natesan

  公开号：US20060063823A1

  公开（公告）日：2006-03-23

  The present invention provides inhibitors of 15-LO according to Formula I, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.

  本发明提供了15-LO的抑制剂，其符合公式I，以及包含这些抑制剂的药物组合物，并且使用这些化合物和组合物治疗与15-LO级联相关的疾病的方法。
• NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF
  申请人：Daegu-Gyeongbuk Medical Innovation Foundation

  公开号：EP4065553A1

  公开（公告）日：2022-10-05
• US7754755B2
  申请人：——

  公开号：US7754755B2

  公开（公告）日：2010-07-13
• Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors
  作者：Xiaoke Guo、Qian Yang、Jing Xu、Li Zhang、Hongxi Chu、Peng Yu、Yingying Zhu、Jinglian Wei、Weilin Chen、Yaozhong Zhang、Xiaojin Zhang、Haopeng Sun、Yiqun Tang、Qidong You

  DOI：10.1016/j.bmc.2013.08.041

  日期：2013.11

  Atrial fibrillation (AF) is one of the common arrhythmias that threaten human health. Kv1.5 potassium channel is reported as an efficacious and safe target for the treatment of AF. In this paper, we designed and synthesized three series of compounds through modifying the lead compound RH01617 that was screened out by the pharmacophore model we reported earlier. All of the compounds were evaluated by the whole-patch lamp technology and most of them possessed potent inhibitory activities against Kv1.5. Compounds IIIi and IIIl were evaluated for the target selectivity as well as the pharmacodynamic effects in an isolated rat model. Due to the promising pharmacological behavior, compound IIIl deserves further pharmacodynamic and pharmacokinetic evaluations. (C) 2013 Elsevier Ltd. All rights reserved.